Introducing Pα+: learn more and subscribe today.

Psychedelics Company Profiles

Click on a company name below to view key financials, press releases and interviews.

ATAI Life Sciences

Beckley Psytech

Better Plant Sciences (PLNT)

CaaMTech

Champignon Brands Inc. (SHRM)

COMPASS Pathways (CMPS)

Cybin Inc.

Eleusis

Entheon Biomedical

Field Trip (FTRP)

Havn Life (HAVN)

Hollister Biosciences (HOLL)

MagicMed Industries

MindMed (MMED)

Mydecine Innovations Group (MYCO)

Numinus (NUMI)

Revive Therapeutics Ltd. (RVV)

Pα+ Psychedelic Bulletin #150: Drug Development and Research UpdatesNovember 29, 2023
GH Research’s Lead 5-MeO-DMT Candidate Faces Development Hiccup • Psychae Therapeutics Scores AUD $4.5m to Develop DMT-Based Candidate • Cybin Closes $30m Offering • Grants Awarded to 8 ‘Young Investigators’ Exploring Psychedelics • atai Buys Out Remainder of DemeRx’s Ibogaine Asset; Announces Novel 5-HT2A Agonist Candidates • Compass Commences UK Portion of Phase 3 Trial, Officially Opens London Centre • Awakn Plans to Commence Enrollment for Phase 3 Study of Ketamine for Severe Alcohol Use Disorder in Q1 2024 • 14% of travellers are interested in a psychedelic retreat in 2024
Pα+ Psychedelic Patent Analysis (October 2023)November 24, 2023
This month: MindMed scores psilocybin-antidepressant co-treatment patent • A spate of PCTs published from GH Research • Early fruits of Cybin's Small Pharma acquisition • and more...
Pα+ Mini Interview with Ester Kincová and Steve Rolles: Regulating the Non-Medical Use of PsychedelicsNovember 20, 2023
We spoke to Ester Kincová and Steve Rolles from Transform Policy Foundation, co-authors of a new publication, 'How to Regulate Psychedelics'. We sought to better understand their perspectives on emergent international psychedelic policy ‘experiments’ and broader contexts.
Pα+ Mini Interview with Eddie Jacobs: Post-Trial Provisions in Clinical Psychedelic ResearchNovember 20, 2023
Earlier this month Eddie Jacobs et al. published an article in Neuroethics titled, When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research. We asked Jacobs a few questions about the current and potential state of post-clinical-trial support.
Pα+ Psychedelic Bulletin #149: Worldwide Psychedelic Policy DevelopmentsNovember 17, 2023
TREAT Retreats • Wiener Regroups: Decrim. Off the Agenda • California Psilocybin Decrim. Initiative Continues Signature Gathering • Veterans’ Affairs Subcommittee on Health Discusses Psychedelics • Canadian Senate Subcommittee on Veterans Affairs: “The Time is Now” to Fund Psychedelic Research • Transform Publishes “Practical Guide” to Regulating Psychedelics • UK Government Responds to Drugs Committee’s Report • Other Policy-Related News

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.